India’s first indigenously developed vaccine against cervical cancer will hit the market soon


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
India’s first indigenously developed human papillomavirus (HPV) vaccine will be soon administered to women in near future. The research and development related to vaccines have been completed and SII will start manufacturing the vaccine soon.

India’s first indigenously developed quadrivalent human papillomavirus (HPV) vaccine for cervical cancer prevention will be available in the market in near future. Union Minister of State of Science & Technology Jitendra Singh informed that research and development related to vaccines is completed and now the next step of mass production would take place. 

Cervical cancer occurs in the cells of the cervix. It is mainly because of the sexually transmitted infection caused by the human papillomavirus (HPV). The vaccine can prevent the complications caused by the virus in girls and women. In addition to this, the vaccine is protective against vulvar and vaginal cancer also. 

According to WHO’s International Agency for Research on Cancer, cervical cancer is the second most common type of cancer across the world. India holds about a fifth of the global burden of cervical cancer. India witnesses 1.2 lakhs cases of cervical cancer with approx. 60,000 deaths per year.

The Quadrivalent Human Papillomavirus vaccine (qHPV) is developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT).

The Drugs Controller General of India (DCGI) has given market authorization to the Serum Institute of India (SII) to manufacture vaccines against cervical cancer. The vaccine rates will be very much affordable and would cost in the range of Rs 200-400. However, the final price is not yet decided. Firstly, the vaccine would be given in India and after that, it will be exported to other countries. 

Currently, two HPV vaccines by foreign manufacturers are available in India - the quadrivalent vaccine (Gardasil Merck), priced at Rs 2,800 per dose; and a bivalent vaccine (Cervarix from GlaxoSmithKline), priced at Rs 3,299 per dose.

Considering the high prevalence rate of typhoid, the government is trying hard to bring something to its rescue. The central government is also considering including the HPV vaccine and typhoid vaccine in the Universal Vaccination Programme (must for all).

Tags : #HPVvaccine #Humanpapillomavirus #Cervicalcancer #STI #Cervicalcancervaccine #Cervicalcancernews #Medicircle #SmitaKumar #Healthcareupdates #Researchanddevelopment #Vaccinedevelopment

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026